Bronchial Thermoplasty Global Registry (BTGR) : 2-year results
Torrego, Alfons (Institut d'Investigació Biomèdica Sant Pau)
Herth, Felix J. (Thoraxklinik University of Heidelberg)
Munoz-Fernandez, Ana M. (Hospital Universitari de Girona Doctor Josep Trueta)
Puente, Luis (Hospital General Universitario Gregorio Marañón)
Facciolongo, Nicola (IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia (Itàlia))
Bicknell, Stephen (Respiratory Department. Gartnavel General Hospital)
Novali, Mauro (Azienda Ospedaliera Spedali Civili di Brescia (Brescia, Itàlia))
Gasparini, Stefano (Respiratory Department. Università Politecnica Delle Marche)
Bonifazi, Martina (Respiratory Department. Università Politecnica Delle Marche)
Dheda, Keertan (Respiratory Department. University of Cape Town)
Andreo García, Felipe (Institut Germans Trias i Pujol)
Votruba, Praha (Respiratory Department. Klinika Tuberkulozy A Respiracnich Onemocneni)
Langton, David (Frankston Hospital Peninsula Health (Frankston, Austràlia))
Flandes, Javier (Hospital Universitario Fundación Jiménez Díaz)
Fielding, David (Royal Brisbane and Women's Hospital)
Bonta, Peter I. (Amsterdam University Medical Center (UMC))
Skowasch, Dirk (Department of Cardiology and Pneumology. University of Bonn)
Schulz, Christian (Respiratory Department. University Hospital Regensburg)
Darwiche, Kaid (Respiratory Department. Ruhrlandklinik - West German Lung Center. University Medicine Essen)
McMullen, Edmund (Boston Scientific Corp)
Grubb, G. Mark (Boston Scientific Corp)
Niven, Robert (Respiratory Department. Central Manchester University Hospitals NHS Foundation Trust)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Objectives Bronchial thermoplasty (BT) is a device-based treatment for subjects ≥18 years with severe asthma not well controlled with inhaled corticosteroids and long-acting beta-agonists. The Bronchial Thermoplasty Global Registry (BTGR) collected real-world data on subjects undergoing this procedure. Design The BTGR is an all-comer, prospective, open-label, multicentre study enrolling adult subjects indicated for and treated with BT. Setting Eighteen centres in Spain, Italy, Germany, the UK, the Netherlands, the Czech Republic, South Africa and Australia Participants One hundred fifty-seven subjects aged 18 years and older who were scheduled to undergo BT treatment for asthma. Subjects diagnosed with other medical conditions which, in the investigator's opinion, made them inappropriate for BT treatment were excluded. Primary and secondary outcome measures Baseline characteristics collected included demographics, Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), medication usage, forced expiratory volume in one second and forced vital capacity, medical history, comorbidities and 12-month baseline recall data (severe exacerbations (SE) and healthcare utilisation). SE incidence and healthcare utilisation were summarised at 1 and 2 years post-BT. Results Subjects' baseline characteristics were representative of persons with severe asthma. A comparison of the proportion of subjects experiencing events during the 12 months prior to BT to the 2-year follow-up showed a reduction in SE (90. 3% vs 56. 1%, p<0. 0001), emergency room visits (53. 8% vs 25. 5%, p<0. 0001) and hospitalisations (42. 9% vs 23. 5 %, p=0. 0019). Reductions in asthma maintenance medication dosage were also observed. AQLQ and ACT scores improved from 3. 26 and 11. 18 at baseline to 4. 39 and 15. 54 at 2 years, respectively (p<0. 0001 for both AQLQ and ACT). Conclusions The BTGR demonstrates sustained improvement in clinical outcomes and reduction in asthma medication usage 2 years after BT in a real-world population. This is consistent with results from other BT randomised controlled trials and registries and further supports improvement in asthma control after BT. Trial registration number NCT02104856.
Nota:	Funding This study was sponsored by Boston Scientific Corporation, Marlborough, MA, USA.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Asthma ; Bronchoscopy ; Chronic airways disease
Publicat a:	BMJ open, Vol. 11 Núm. 12 (january 2021) , p. e053854, ISSN 2044-6055

DOI: 10.1136/bmjopen-2021-053854
PMID: 34916324

8 p, 329.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats